Read More

MindBio take-home LSD trial sees 60% depression drop

MindBio Therapeutics Corp. (CSE: MBIO) posted positive outcomes from its Phase 2a clinical trial involving the take-home microdosing of its depression treatment drug, MB22001. According to the company’s announcement on Monday, the trial achieved its primary efficacy endpoint, with participants experiencing a mean 14.1 point reduction in the Montgomery-Asberg Depression …